Systematic review of ablative therapy for the treatment of renal allograft neoplasms

Evaldo Favi, Nicholas Raison, Federico Ambrogi, Serena Delbue, Maria Chiara Clementi, Luca Lamperti, Marta Perego, Matteo Bischeri, Mariano Ferraresso

Research output: Contribution to journalReview article

Abstract

BACKGROUND To date, there are no guidelines on the treatment of solid neoplasms in the transplanted kidney. Historically, allograft nephrectomy has been considered the only reasonable option. More recently, nephron-sparing surgery (NSS) and ablative therapy (AT) have been proposed as alternative procedures in selected cases. AIM To review outcomes of AT for the treatment of renal allograft tumours. METHODS We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 Checklist. PubMed was searched in March 2019 without time restrictions for all papers reporting on radiofrequency ablation (RFA), cryoablation (CA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) of solid tumours of the kidney allograft. Only original manuscripts describing actual cases and edited in English were considered. All relevant articles were accessed in full text. Additional searches included all pertinent references. Selected studies were also assessed for methodological quality using a tool based on a modification of the Newcastle Ottawa scale. Data on recipient characteristics, transplant characteristics, disease characteristics, treatment protocols, and treatment outcomes were extracted and analysed. Given the nature and the quality of the studies available (mostly retrospective case reports and small retrospective uncontrolled case series), a descriptive summary was provided. RESULTS Twenty-eight relevant studies were selected describing a total of 100 AT procedures in 92 patients. Recipient age at diagnosis ranged from 21 to 71 years whereas time from transplant to diagnosis ranged from 0.1 to 312 mo. Most of the neoplasms were asymptomatic and diagnosed incidentally during imaging carried out for screening purposes or for other clinical reasons. Preferred diagnostic modality was Doppler-ultrasound scan followed by computed tomography scan, and magnetic resonance imaging. Main tumour types were: papillary renal cell carcinoma (RCC) and clear cell RCC. Maximal tumour diameter ranged from 5 to 55 mm. The vast majority of neoplasms were T1a N0 M0 with only 2 lesions staged T1b N0 M0. Neoplasms were managed by RFA (n = 78), CA (n = 15), MWA (n = 3), HIFU (n = 3), and IRE (n = 1). Overall, 3 episodes of primary treatment failure were reported. A single case of recurrence was identified. Follow-up ranged from 1 to 81 mo. No cancer-related deaths were observed. Complication rate was extremely low (mostly < 10%). Graft function remained stable in the majority of recipients. Due to the limited sample size, no clear benefit of a single procedure over the other ones could be demonstrated. CONCLUSION AT for renal allograft neoplasms represents a promising alternative to radical nephrectomy and NSS in carefully selected patients. Properly designed clinical trials are needed to validate this therapeutic approach.

Original languageEnglish
Pages (from-to)2487-2504
Number of pages18
JournalWorld Journal of Clinical Cases
Volume7
Issue number17
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Kidney Neoplasms
Allografts
Neoplasms
Cryosurgery
Electroporation
Therapeutics
Nephrons
Microwaves
Nephrectomy
Kidney
Renal Cell Carcinoma
High-Intensity Focused Ultrasound Ablation
Transplants
Doppler Ultrasonography
Manuscripts
Clinical Protocols
Treatment Failure
Checklist
PubMed
Sample Size

Keywords

  • Ablative therapy
  • Cryoablation
  • High-intensity focused ultrasonography
  • Irreversible electroporation
  • Kidney transplant
  • Microwave ablation
  • Neoplasm
  • Radiofrequency ablation
  • Renal allograft
  • Systematic review

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Systematic review of ablative therapy for the treatment of renal allograft neoplasms. / Favi, Evaldo; Raison, Nicholas; Ambrogi, Federico; Delbue, Serena; Clementi, Maria Chiara; Lamperti, Luca; Perego, Marta; Bischeri, Matteo; Ferraresso, Mariano.

In: World Journal of Clinical Cases, Vol. 7, No. 17, 01.09.2019, p. 2487-2504.

Research output: Contribution to journalReview article

Favi, E, Raison, N, Ambrogi, F, Delbue, S, Clementi, MC, Lamperti, L, Perego, M, Bischeri, M & Ferraresso, M 2019, 'Systematic review of ablative therapy for the treatment of renal allograft neoplasms', World Journal of Clinical Cases, vol. 7, no. 17, pp. 2487-2504. https://doi.org/10.12998/wjcc.v7.i17.2487
Favi, Evaldo ; Raison, Nicholas ; Ambrogi, Federico ; Delbue, Serena ; Clementi, Maria Chiara ; Lamperti, Luca ; Perego, Marta ; Bischeri, Matteo ; Ferraresso, Mariano. / Systematic review of ablative therapy for the treatment of renal allograft neoplasms. In: World Journal of Clinical Cases. 2019 ; Vol. 7, No. 17. pp. 2487-2504.
@article{e2c62a6a163b4692b0c77838db59ddea,
title = "Systematic review of ablative therapy for the treatment of renal allograft neoplasms",
abstract = "BACKGROUND To date, there are no guidelines on the treatment of solid neoplasms in the transplanted kidney. Historically, allograft nephrectomy has been considered the only reasonable option. More recently, nephron-sparing surgery (NSS) and ablative therapy (AT) have been proposed as alternative procedures in selected cases. AIM To review outcomes of AT for the treatment of renal allograft tumours. METHODS We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 Checklist. PubMed was searched in March 2019 without time restrictions for all papers reporting on radiofrequency ablation (RFA), cryoablation (CA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) of solid tumours of the kidney allograft. Only original manuscripts describing actual cases and edited in English were considered. All relevant articles were accessed in full text. Additional searches included all pertinent references. Selected studies were also assessed for methodological quality using a tool based on a modification of the Newcastle Ottawa scale. Data on recipient characteristics, transplant characteristics, disease characteristics, treatment protocols, and treatment outcomes were extracted and analysed. Given the nature and the quality of the studies available (mostly retrospective case reports and small retrospective uncontrolled case series), a descriptive summary was provided. RESULTS Twenty-eight relevant studies were selected describing a total of 100 AT procedures in 92 patients. Recipient age at diagnosis ranged from 21 to 71 years whereas time from transplant to diagnosis ranged from 0.1 to 312 mo. Most of the neoplasms were asymptomatic and diagnosed incidentally during imaging carried out for screening purposes or for other clinical reasons. Preferred diagnostic modality was Doppler-ultrasound scan followed by computed tomography scan, and magnetic resonance imaging. Main tumour types were: papillary renal cell carcinoma (RCC) and clear cell RCC. Maximal tumour diameter ranged from 5 to 55 mm. The vast majority of neoplasms were T1a N0 M0 with only 2 lesions staged T1b N0 M0. Neoplasms were managed by RFA (n = 78), CA (n = 15), MWA (n = 3), HIFU (n = 3), and IRE (n = 1). Overall, 3 episodes of primary treatment failure were reported. A single case of recurrence was identified. Follow-up ranged from 1 to 81 mo. No cancer-related deaths were observed. Complication rate was extremely low (mostly < 10{\%}). Graft function remained stable in the majority of recipients. Due to the limited sample size, no clear benefit of a single procedure over the other ones could be demonstrated. CONCLUSION AT for renal allograft neoplasms represents a promising alternative to radical nephrectomy and NSS in carefully selected patients. Properly designed clinical trials are needed to validate this therapeutic approach.",
keywords = "Ablative therapy, Cryoablation, High-intensity focused ultrasonography, Irreversible electroporation, Kidney transplant, Microwave ablation, Neoplasm, Radiofrequency ablation, Renal allograft, Systematic review",
author = "Evaldo Favi and Nicholas Raison and Federico Ambrogi and Serena Delbue and Clementi, {Maria Chiara} and Luca Lamperti and Marta Perego and Matteo Bischeri and Mariano Ferraresso",
year = "2019",
month = "9",
day = "1",
doi = "10.12998/wjcc.v7.i17.2487",
language = "English",
volume = "7",
pages = "2487--2504",
journal = "World Journal of Clinical Cases",
issn = "2307-8960",
publisher = "Baishideng Publishing Group",
number = "17",

}

TY - JOUR

T1 - Systematic review of ablative therapy for the treatment of renal allograft neoplasms

AU - Favi, Evaldo

AU - Raison, Nicholas

AU - Ambrogi, Federico

AU - Delbue, Serena

AU - Clementi, Maria Chiara

AU - Lamperti, Luca

AU - Perego, Marta

AU - Bischeri, Matteo

AU - Ferraresso, Mariano

PY - 2019/9/1

Y1 - 2019/9/1

N2 - BACKGROUND To date, there are no guidelines on the treatment of solid neoplasms in the transplanted kidney. Historically, allograft nephrectomy has been considered the only reasonable option. More recently, nephron-sparing surgery (NSS) and ablative therapy (AT) have been proposed as alternative procedures in selected cases. AIM To review outcomes of AT for the treatment of renal allograft tumours. METHODS We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 Checklist. PubMed was searched in March 2019 without time restrictions for all papers reporting on radiofrequency ablation (RFA), cryoablation (CA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) of solid tumours of the kidney allograft. Only original manuscripts describing actual cases and edited in English were considered. All relevant articles were accessed in full text. Additional searches included all pertinent references. Selected studies were also assessed for methodological quality using a tool based on a modification of the Newcastle Ottawa scale. Data on recipient characteristics, transplant characteristics, disease characteristics, treatment protocols, and treatment outcomes were extracted and analysed. Given the nature and the quality of the studies available (mostly retrospective case reports and small retrospective uncontrolled case series), a descriptive summary was provided. RESULTS Twenty-eight relevant studies were selected describing a total of 100 AT procedures in 92 patients. Recipient age at diagnosis ranged from 21 to 71 years whereas time from transplant to diagnosis ranged from 0.1 to 312 mo. Most of the neoplasms were asymptomatic and diagnosed incidentally during imaging carried out for screening purposes or for other clinical reasons. Preferred diagnostic modality was Doppler-ultrasound scan followed by computed tomography scan, and magnetic resonance imaging. Main tumour types were: papillary renal cell carcinoma (RCC) and clear cell RCC. Maximal tumour diameter ranged from 5 to 55 mm. The vast majority of neoplasms were T1a N0 M0 with only 2 lesions staged T1b N0 M0. Neoplasms were managed by RFA (n = 78), CA (n = 15), MWA (n = 3), HIFU (n = 3), and IRE (n = 1). Overall, 3 episodes of primary treatment failure were reported. A single case of recurrence was identified. Follow-up ranged from 1 to 81 mo. No cancer-related deaths were observed. Complication rate was extremely low (mostly < 10%). Graft function remained stable in the majority of recipients. Due to the limited sample size, no clear benefit of a single procedure over the other ones could be demonstrated. CONCLUSION AT for renal allograft neoplasms represents a promising alternative to radical nephrectomy and NSS in carefully selected patients. Properly designed clinical trials are needed to validate this therapeutic approach.

AB - BACKGROUND To date, there are no guidelines on the treatment of solid neoplasms in the transplanted kidney. Historically, allograft nephrectomy has been considered the only reasonable option. More recently, nephron-sparing surgery (NSS) and ablative therapy (AT) have been proposed as alternative procedures in selected cases. AIM To review outcomes of AT for the treatment of renal allograft tumours. METHODS We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 Checklist. PubMed was searched in March 2019 without time restrictions for all papers reporting on radiofrequency ablation (RFA), cryoablation (CA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) of solid tumours of the kidney allograft. Only original manuscripts describing actual cases and edited in English were considered. All relevant articles were accessed in full text. Additional searches included all pertinent references. Selected studies were also assessed for methodological quality using a tool based on a modification of the Newcastle Ottawa scale. Data on recipient characteristics, transplant characteristics, disease characteristics, treatment protocols, and treatment outcomes were extracted and analysed. Given the nature and the quality of the studies available (mostly retrospective case reports and small retrospective uncontrolled case series), a descriptive summary was provided. RESULTS Twenty-eight relevant studies were selected describing a total of 100 AT procedures in 92 patients. Recipient age at diagnosis ranged from 21 to 71 years whereas time from transplant to diagnosis ranged from 0.1 to 312 mo. Most of the neoplasms were asymptomatic and diagnosed incidentally during imaging carried out for screening purposes or for other clinical reasons. Preferred diagnostic modality was Doppler-ultrasound scan followed by computed tomography scan, and magnetic resonance imaging. Main tumour types were: papillary renal cell carcinoma (RCC) and clear cell RCC. Maximal tumour diameter ranged from 5 to 55 mm. The vast majority of neoplasms were T1a N0 M0 with only 2 lesions staged T1b N0 M0. Neoplasms were managed by RFA (n = 78), CA (n = 15), MWA (n = 3), HIFU (n = 3), and IRE (n = 1). Overall, 3 episodes of primary treatment failure were reported. A single case of recurrence was identified. Follow-up ranged from 1 to 81 mo. No cancer-related deaths were observed. Complication rate was extremely low (mostly < 10%). Graft function remained stable in the majority of recipients. Due to the limited sample size, no clear benefit of a single procedure over the other ones could be demonstrated. CONCLUSION AT for renal allograft neoplasms represents a promising alternative to radical nephrectomy and NSS in carefully selected patients. Properly designed clinical trials are needed to validate this therapeutic approach.

KW - Ablative therapy

KW - Cryoablation

KW - High-intensity focused ultrasonography

KW - Irreversible electroporation

KW - Kidney transplant

KW - Microwave ablation

KW - Neoplasm

KW - Radiofrequency ablation

KW - Renal allograft

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85072326241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072326241&partnerID=8YFLogxK

U2 - 10.12998/wjcc.v7.i17.2487

DO - 10.12998/wjcc.v7.i17.2487

M3 - Review article

AN - SCOPUS:85072326241

VL - 7

SP - 2487

EP - 2504

JO - World Journal of Clinical Cases

JF - World Journal of Clinical Cases

SN - 2307-8960

IS - 17

ER -